India to launch world's first intranasal vaccine for COVID-19

23 January 2023

Indian homegrown vaccine maker Bharat Biotech is to launch its intranasal COVID-19 vaccine, iNCOVACC (BBV154), on January 26, on the occasion of India's Republic Day, claiming it is the world's first intranasal vaccine for COVID-19.

The company is to sell the intranasal vaccine for $4 per shot for procurement by the government and $9.84 for private vaccination centers.

Chairman and managing director Dr Krishna Ella termed it a global game changer in intranasal vaccine technology and delivery systems. "Despite the lack of demand for COVID-19 vaccines, we continued product development in intranasal vaccines to ensure that we are well prepared with platform technologies for future infectious diseases," he said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK